



Jupiter Neurosciences, Inc.

(NASDAQ: JUNS)

March 2026



CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS

This Presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. Factors that could cause such differences, but are not limited to, are our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management, expected market growth, our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this Presentation and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.

MARKET, INDUSTRY AND OTHER DATA

This presentation includes market and industry data and forecasts that the Company has developed from independent research reports, publicly available information, various industry publications, other published industry sources or the Company’s internal data and estimates. Independent research reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Although the Company believes that the publications and reports are reliable, the Company has not independently verified the data and makes no representation or warranty with respect to the accuracy of such information. Any and all trademarks and trade names referred to in this presentation are the property of their respective owners. The Company’s internal data, estimates and forecasts are based on information obtained from trade and business organizations and other contracts in the markets in which it operates and management’s understanding of industry conditions. Although the Company believes that such information is reliable, the Company has not had such information verified by any independent sources.



Highlights

Founded 2016 with a goal of making resveratrol more bioavailable

Breakthrough Therapeutics Platform — JOTROL™: 2021 Phase 1 study proved success w. 9X bioavailability. Patent protected through 2036

Clinical Pipeline: Parkinson's Phase IIa trial is in process. Post PD results, we expect to target Mild Cognitive Impairment/early AD.

Dual-Engine Strategy: Therapeutics + Consumer Longevity & Aging: Recently launched **Nugevia™**, a direct-to-consumer longevity supplement line based on JOTROL™. Tapping into a **Global longevity** market with explosive growth

Financing through \$11 M IPO + recent \$20 M SEPA

IPO: December 4, 2024

SEPA: October 24, 2025 (\$6 M advance + ELOC)

JOTROL™ vs Resveratrol



JOTROL™ - Broad Applicability Across Disease Areas

Alzheimer's Disease

Target: Neuroinflammation and cognitive decline

Longevity & Healthspan

Target: Extending healthy aging through reduction of inflammation and increase of mitochondria

Mental Health

Target: Neuroinflammation's role in psychiatric conditions



Parkinson's Disease

Target: Addressing motor symptoms and neurodegeneration

Rare Diseases

Target: MPS-1 and MELAS




Mitochondrial Disorders

Target: Restoring cellular energy production

JOTROL™ is Neuroprotective

Motor Dysfunction in MPTP Model of PD

CONCLUSION: JOTROL™ DEMONSTRATES BENEFICIAL NEUROLOGIC EFFECTS IN PD



Phase 2a Clinical Advisory Board

Phase 2a, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Resveratrol (JOTROL™) in Parkinson's Disease (RESET)

Charbel Moussa, MBBS, PhD- Zina Biopharmaceuticals, Consultant

Fernando Pagan, MD- Director, Movement Disorders Clinic- MedStar Georgetown University Hospital, Washington DC

Yassar Torres-Yaghi, MD, Director, Parkinsonism and Dementia Clinic, MedStar Georgetown University Hospital. McLain Virginia

Fahad Amjad, MD, Director, Movement Disorders Clinic- MedStar Research Institute, Olney Hospital

Gary Volkell, MD, Movement Disorders Clinic- MedStar Research Institute, Franklin Square Hospital, Baltimore



Titration and Dosing

	Week 1 (QD capsules)	Week 2 (QD capsules)	Week 3 (QD capsules)	Week 4 (QD capsules)	Week 5-12 (QD capsules)
Arm A (placebo)	4x placebo	4x placebo	4x placebo	4x placebo	4x placebo
Arm B-200mg	3x placebo 1x100mg JOTROL™	2x placebo 2x100mg JOTROL™	2x placebo 2x100mg JOTROL™	2x placebo 2x100mg JOTROL™	2x placebo 2x100mg JOTROL™
Arm C-400mg	3x placebo 1x100mg JOTROL™	2x placebo 2x100mg JOTROL™	1x placebo 3x100mg JOTROL™	4x100mg JOTROL™	4x100mg JOTROL™

Phase IIA JOTROL™ PD Study

➤ Trial Design

- 30 PD patients
- Randomized into placebo/MAD design
- Oral administration of study drug
- Once daily administration over the course of 12 weeks

➤ Study Objectives

- Primary Objectives – Safety and Pharmacokinetics
- Secondary Objectives – Biomarker and Target Engagement
- Exploratory Objectives – Clinical outcomes via MDS-UPDRS, MoCA, TUG, CGI, PDQ-39, NLRP3

PD Trial Timelines – red indicates current status

- IND by the FDA—granted November '25
- FPS (First Patient Screened)—expected April '26
- FPPD (First Patient First Dose)—expected May '26
- LPLV (Last Patient Last Visit) anticipated – expected Late '26
- Top-Line results – expected Late 26'

Nugevia™ - DTC Consumer Supplements

- Nugevia™ positions **JUNS** in the **Global longevity** market, with premium formulations designed for compliance and high margins
- JOTROL™ resveratrol is a key ingredient in all products



High-profile brand ambassadors and scientists enhancing credibility and reach.



- **Annika Sörenstam**, the most accomplished female professional golfer in history, joined Nugevia as its first brand ambassador.
- **Chris Webber**, NBA Hall of Famer and five-time All-Star
- **Jean Fallacara**, CEO/Owner of Lifespanning Magazine, Biohacker

Nugevia™ Markets

- **Longevity & Aging market:** Explosive \$T growth market including a fast-growing nutritional market'
- **Existing Resveratrol market:** \$300M + in existing sales.
- **Alzheimer's and Parkinson's market:** Customers with early onset of disease or has prevalence within their family have already ordered Nugevia™.
- **Compounding Pharmacies:** GLP-1 users experience several issues that a Nugevia™ stack might resolve. Annual sales of nutritional products through compounding pharmacies are ~ \$1 B annually
- Nugevia™ supports the biology required to stay healthy as long as you live

Dual Approach Summary

- Biotech:
 - Successful PD Trial completion in late 2026 might trigger strategic partnership discussions and start of MCI Phase II trial.
- Longevity & Aging:
 - Digital marketing started (META, Google etc.)
 - Compounding pharmacy market as complementary distribution.
 - High-end wellness and Spa's. Fast Growing segment looking for science backed products.

Dual Approach keeps the high Biotech exit possibility while the Longevity/DTC creates positive (2027) cash-flow

Thank You

NASDAQ: JUNS

Contacts:

c.rosen@jupiterneurosciences.com

a.rosen@jupiterneurosciences.com

a.silva@jupiterneurosciences.com

